Study wrapper · #144
Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Editor's note
A large systematic review and network meta-analysis of 13 RCTs (97,428 participants; 31,846 with confirmed CKD) evaluating GLP-1 receptor agonists for cardiorenal outcomes, anchored by the landmark FLOW trial. Researchers reported the class reduced MACE by 16% (HR 0.84) and a composite kidney endpoint by 21% (HR 0.79), both graded high certainty by GRADE, with kidney-failure risk down 28% and albuminuria down 26%; benefits were consistent regardless of SGLT2-inhibitor background, and no excess acute kidney injury was seen. Semaglutide ranked highest in the network (SUCRA 78.4%). Two caveats worth holding: cross-trial network rankings are indirect and can be fragile, so the SUCRA ordering is weaker than the direct pooled estimates; and class-level evidence is driven by specific agents. Weight this as strong, high-certainty randomized evidence for cardiorenal protection in CKD, with the head-to-head "best agent" claim carrying more uncertainty than the class-level benefit.
Plain-language abstract
This review combined 13 randomized trials with over 97,000 participants (about 31,800 with confirmed chronic kidney disease) to see how GLP-1 medicines affect heart and kidney outcomes in people with kidney disease. Pooling the trials, these drugs lowered the risk of major heart events by 16% and a combined measure of kidney problems by 21%, findings the authors rated as high quality. The risk of kidney failure dropped by 28%, and a marker of kidney damage in the urine fell by 26%. The benefits held whether or not people were also taking another kidney-protective drug class (SGLT2 inhibitors), and there was no increase in sudden kidney injury. In a statistical ranking that compared drugs indirectly, injectable semaglutide came out on top for kidney outcomes. The authors note the direct semaglutide evidence is high quality, while the "which drug is best" ranking is a less certain, exploratory comparison.